Concepts (189)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Kidney Transplantation | 21 | 2022 | 839 | 4.290 |
Why?
|
| Pancreas Transplantation | 4 | 2021 | 71 | 2.200 |
Why?
|
| Graft Rejection | 10 | 2021 | 458 | 1.840 |
Why?
|
| Graft Survival | 8 | 2022 | 465 | 1.460 |
Why?
|
| Tissue and Organ Procurement | 2 | 2022 | 164 | 1.290 |
Why?
|
| Histocompatibility Testing | 2 | 2020 | 38 | 1.240 |
Why?
|
| Patient Selection | 2 | 2020 | 592 | 1.090 |
Why?
|
| Diabetes Mellitus, Type 1 | 2 | 2019 | 529 | 0.960 |
Why?
|
| Arteriovenous Shunt, Surgical | 2 | 2020 | 31 | 0.910 |
Why?
|
| Retrospective Studies | 17 | 2022 | 7277 | 0.790 |
Why?
|
| Postoperative Complications | 5 | 2020 | 1615 | 0.790 |
Why?
|
| Music Therapy | 1 | 2020 | 2 | 0.760 |
Why?
|
| Donor Selection | 2 | 2022 | 29 | 0.740 |
Why?
|
| CD40 Ligand | 1 | 2020 | 14 | 0.740 |
Why?
|
| Renal Dialysis | 2 | 2021 | 174 | 0.740 |
Why?
|
| Conscious Sedation | 1 | 2020 | 61 | 0.720 |
Why?
|
| T-Lymphocytes, Cytotoxic | 1 | 2020 | 79 | 0.710 |
Why?
|
| Diabetes Mellitus, Type 2 | 2 | 2019 | 1085 | 0.700 |
Why?
|
| Renal Insufficiency | 1 | 2020 | 121 | 0.680 |
Why?
|
| Opioid-Related Disorders | 2 | 2020 | 298 | 0.680 |
Why?
|
| Liver Transplantation | 3 | 2022 | 400 | 0.650 |
Why?
|
| Adenocarcinoma | 2 | 2013 | 475 | 0.610 |
Why?
|
| Anxiety | 1 | 2020 | 422 | 0.590 |
Why?
|
| Adult | 19 | 2022 | 21403 | 0.590 |
Why?
|
| Histocompatibility | 1 | 2016 | 17 | 0.550 |
Why?
|
| Isoantibodies | 1 | 2016 | 35 | 0.550 |
Why?
|
| HLA Antigens | 1 | 2016 | 82 | 0.530 |
Why?
|
| Health Services Accessibility | 1 | 2020 | 581 | 0.530 |
Why?
|
| Epitopes | 1 | 2016 | 146 | 0.530 |
Why?
|
| Humans | 35 | 2022 | 68618 | 0.490 |
Why?
|
| Male | 22 | 2021 | 37321 | 0.470 |
Why?
|
| Diaphragm | 1 | 2014 | 22 | 0.470 |
Why?
|
| Middle Aged | 18 | 2020 | 21147 | 0.460 |
Why?
|
| Female | 21 | 2021 | 38074 | 0.440 |
Why?
|
| Heart Atria | 1 | 2014 | 206 | 0.430 |
Why?
|
| Telemedicine | 1 | 2020 | 700 | 0.410 |
Why?
|
| Kidney | 6 | 2022 | 945 | 0.410 |
Why?
|
| Pancreatectomy | 1 | 2013 | 129 | 0.400 |
Why?
|
| Aged | 11 | 2020 | 14862 | 0.390 |
Why?
|
| Apolipoprotein L1 | 2 | 2022 | 16 | 0.390 |
Why?
|
| Laryngeal Nerve Injuries | 1 | 2010 | 1 | 0.360 |
Why?
|
| Neuroma | 1 | 2010 | 3 | 0.360 |
Why?
|
| Tacrolimus | 3 | 2020 | 127 | 0.360 |
Why?
|
| Young Adult | 6 | 2020 | 5717 | 0.360 |
Why?
|
| Laryngectomy | 1 | 2010 | 30 | 0.350 |
Why?
|
| Laryngeal Neoplasms | 1 | 2010 | 47 | 0.350 |
Why?
|
| Hemangiosarcoma | 1 | 2010 | 23 | 0.350 |
Why?
|
| Cough | 1 | 2010 | 65 | 0.350 |
Why?
|
| Pancreatic Neoplasms | 1 | 2013 | 332 | 0.340 |
Why?
|
| Longitudinal Studies | 4 | 2021 | 1054 | 0.340 |
Why?
|
| Delayed Graft Function | 2 | 2022 | 39 | 0.340 |
Why?
|
| Penile Neoplasms | 1 | 2009 | 12 | 0.330 |
Why?
|
| Urethral Neoplasms | 1 | 2008 | 2 | 0.320 |
Why?
|
| Hemangioma, Cavernous | 1 | 2008 | 5 | 0.320 |
Why?
|
| Immunosuppressive Agents | 5 | 2020 | 514 | 0.320 |
Why?
|
| Allografts | 2 | 2020 | 63 | 0.320 |
Why?
|
| Common Bile Duct Neoplasms | 1 | 2007 | 12 | 0.290 |
Why?
|
| Treatment Outcome | 7 | 2018 | 7029 | 0.290 |
Why?
|
| Carcinoid Tumor | 1 | 2007 | 20 | 0.290 |
Why?
|
| Ampulla of Vater | 1 | 2007 | 34 | 0.290 |
Why?
|
| Analgesics, Opioid | 2 | 2020 | 498 | 0.250 |
Why?
|
| Risk Factors | 4 | 2019 | 5731 | 0.250 |
Why?
|
| Time Factors | 4 | 2019 | 4655 | 0.250 |
Why?
|
| Waiting Lists | 2 | 2022 | 104 | 0.230 |
Why?
|
| Follow-Up Studies | 4 | 2019 | 3259 | 0.220 |
Why?
|
| Tissue Donors | 2 | 2022 | 195 | 0.220 |
Why?
|
| Aged, 80 and over | 4 | 2020 | 4848 | 0.210 |
Why?
|
| Prostatic Neoplasms | 1 | 2009 | 778 | 0.210 |
Why?
|
| Substance Abuse, Intravenous | 1 | 2022 | 30 | 0.200 |
Why?
|
| Biomarkers | 2 | 2018 | 1593 | 0.200 |
Why?
|
| Policy | 1 | 2022 | 58 | 0.200 |
Why?
|
| Pain, Procedural | 1 | 2020 | 4 | 0.190 |
Why?
|
| Prospective Studies | 2 | 2020 | 3705 | 0.190 |
Why?
|
| Hepatitis C, Chronic | 1 | 2022 | 86 | 0.190 |
Why?
|
| Hepatitis C | 1 | 2022 | 114 | 0.190 |
Why?
|
| Angiotensin Receptor Antagonists | 1 | 2021 | 155 | 0.180 |
Why?
|
| Glomerular Filtration Rate | 2 | 2019 | 274 | 0.180 |
Why?
|
| Kidney Failure, Chronic | 2 | 2020 | 365 | 0.180 |
Why?
|
| Intestinal Perforation | 1 | 2020 | 35 | 0.180 |
Why?
|
| Immunologic Memory | 1 | 2020 | 75 | 0.180 |
Why?
|
| Hypnotics and Sedatives | 1 | 2020 | 96 | 0.180 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 1 | 2020 | 47 | 0.180 |
Why?
|
| Living Donors | 1 | 2022 | 160 | 0.180 |
Why?
|
| Breast Neoplasms | 1 | 2010 | 1536 | 0.180 |
Why?
|
| Antilymphocyte Serum | 2 | 2017 | 52 | 0.170 |
Why?
|
| Arteriovenous Fistula | 1 | 2019 | 25 | 0.170 |
Why?
|
| Nursing Care | 1 | 2019 | 18 | 0.170 |
Why?
|
| C-Peptide | 1 | 2018 | 23 | 0.160 |
Why?
|
| BK Virus | 1 | 2018 | 17 | 0.160 |
Why?
|
| Polyomavirus Infections | 1 | 2018 | 17 | 0.160 |
Why?
|
| Tumor Virus Infections | 1 | 2018 | 32 | 0.160 |
Why?
|
| Opportunistic Infections | 1 | 2018 | 33 | 0.160 |
Why?
|
| Immunocompromised Host | 1 | 2018 | 55 | 0.160 |
Why?
|
| Biliary Atresia | 1 | 2018 | 7 | 0.160 |
Why?
|
| User-Computer Interface | 1 | 2020 | 230 | 0.160 |
Why?
|
| Situs Inversus | 1 | 2018 | 13 | 0.160 |
Why?
|
| Referral and Consultation | 1 | 2020 | 383 | 0.160 |
Why?
|
| Pain, Postoperative | 1 | 2020 | 214 | 0.160 |
Why?
|
| Vena Cava, Inferior | 1 | 2018 | 41 | 0.150 |
Why?
|
| Patient Satisfaction | 1 | 2020 | 378 | 0.150 |
Why?
|
| Prognosis | 2 | 2019 | 2093 | 0.150 |
Why?
|
| Abnormalities, Multiple | 1 | 2018 | 109 | 0.150 |
Why?
|
| Induction Chemotherapy | 1 | 2017 | 39 | 0.150 |
Why?
|
| Quality Improvement | 1 | 2020 | 413 | 0.140 |
Why?
|
| Pancreatitis | 1 | 2018 | 279 | 0.140 |
Why?
|
| Receptors, Interleukin-2 | 1 | 2016 | 42 | 0.140 |
Why?
|
| Delivery of Health Care | 1 | 2020 | 445 | 0.130 |
Why?
|
| Kidney Diseases | 1 | 2018 | 307 | 0.130 |
Why?
|
| Logistic Models | 2 | 2017 | 1420 | 0.130 |
Why?
|
| Area Under Curve | 1 | 2016 | 238 | 0.130 |
Why?
|
| Risk Assessment | 2 | 2019 | 2007 | 0.130 |
Why?
|
| Models, Statistical | 1 | 2019 | 448 | 0.130 |
Why?
|
| Cross-Sectional Studies | 1 | 2022 | 2279 | 0.130 |
Why?
|
| Blood Glucose | 1 | 2018 | 631 | 0.130 |
Why?
|
| Hepatectomy | 1 | 2015 | 58 | 0.130 |
Why?
|
| ROC Curve | 1 | 2016 | 392 | 0.130 |
Why?
|
| Chi-Square Distribution | 1 | 2016 | 546 | 0.120 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2016 | 536 | 0.120 |
Why?
|
| Cholelithiasis | 1 | 2015 | 66 | 0.120 |
Why?
|
| Cholecystectomy, Laparoscopic | 1 | 2015 | 59 | 0.120 |
Why?
|
| Drug Therapy, Combination | 1 | 2016 | 649 | 0.120 |
Why?
|
| Algorithms | 1 | 2020 | 1196 | 0.120 |
Why?
|
| Paralysis | 1 | 2014 | 35 | 0.120 |
Why?
|
| Odds Ratio | 1 | 2016 | 880 | 0.110 |
Why?
|
| Taiwan | 1 | 2013 | 20 | 0.110 |
Why?
|
| Multivariate Analysis | 1 | 2016 | 1046 | 0.110 |
Why?
|
| Cohort Studies | 4 | 2020 | 2358 | 0.110 |
Why?
|
| Pheochromocytoma | 1 | 2012 | 22 | 0.100 |
Why?
|
| Predictive Value of Tests | 1 | 2016 | 1465 | 0.100 |
Why?
|
| Neoplasm Invasiveness | 1 | 2013 | 369 | 0.100 |
Why?
|
| Healthcare Disparities | 1 | 2015 | 378 | 0.100 |
Why?
|
| Liver Neoplasms | 1 | 2015 | 334 | 0.100 |
Why?
|
| Liver Cirrhosis | 1 | 2015 | 301 | 0.100 |
Why?
|
| Urinary Bladder Neoplasms | 1 | 2012 | 138 | 0.100 |
Why?
|
| Hemodynamics | 1 | 2014 | 705 | 0.090 |
Why?
|
| Neoplasm Staging | 1 | 2013 | 800 | 0.090 |
Why?
|
| United States | 5 | 2022 | 7367 | 0.090 |
Why?
|
| Hygiene | 1 | 2010 | 11 | 0.090 |
Why?
|
| Survival Rate | 1 | 2013 | 1056 | 0.090 |
Why?
|
| Mastectomy, Segmental | 1 | 2010 | 64 | 0.090 |
Why?
|
| Postmenopause | 1 | 2010 | 93 | 0.080 |
Why?
|
| Transplant Recipients | 2 | 2020 | 109 | 0.080 |
Why?
|
| Adolescent | 2 | 2018 | 8912 | 0.080 |
Why?
|
| Activities of Daily Living | 1 | 2010 | 319 | 0.080 |
Why?
|
| Urethra | 1 | 2008 | 56 | 0.080 |
Why?
|
| Immunohistochemistry | 1 | 2010 | 1174 | 0.070 |
Why?
|
| Laparotomy | 1 | 2007 | 65 | 0.070 |
Why?
|
| Tomography, X-Ray Computed | 2 | 2014 | 2324 | 0.070 |
Why?
|
| Diagnosis, Differential | 1 | 2010 | 1140 | 0.070 |
Why?
|
| Abdominal Pain | 1 | 2007 | 97 | 0.070 |
Why?
|
| Neoplasm Metastasis | 1 | 2007 | 306 | 0.070 |
Why?
|
| Biopsy | 1 | 2007 | 540 | 0.060 |
Why?
|
| Incidence | 2 | 2019 | 1603 | 0.060 |
Why?
|
| Hypertension | 1 | 2012 | 1535 | 0.050 |
Why?
|
| Hepacivirus | 1 | 2022 | 90 | 0.050 |
Why?
|
| Attitude | 1 | 2022 | 121 | 0.050 |
Why?
|
| South Carolina | 2 | 2019 | 2752 | 0.050 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 1 | 2021 | 202 | 0.050 |
Why?
|
| Rituximab | 1 | 2020 | 61 | 0.040 |
Why?
|
| Methotrexate | 1 | 2020 | 91 | 0.040 |
Why?
|
| Antiviral Agents | 1 | 2022 | 211 | 0.040 |
Why?
|
| Kidney Function Tests | 1 | 2019 | 114 | 0.040 |
Why?
|
| Genetic Testing | 1 | 2020 | 159 | 0.040 |
Why?
|
| Drug Administration Schedule | 1 | 2020 | 567 | 0.040 |
Why?
|
| Delivery of Health Care, Integrated | 1 | 2019 | 77 | 0.040 |
Why?
|
| Transplantation, Homologous | 1 | 2019 | 242 | 0.040 |
Why?
|
| Forecasting | 1 | 2019 | 277 | 0.040 |
Why?
|
| Muromonab-CD3 | 1 | 2017 | 8 | 0.040 |
Why?
|
| Alemtuzumab | 1 | 2017 | 10 | 0.040 |
Why?
|
| Health Care Costs | 1 | 2020 | 346 | 0.040 |
Why?
|
| Disease Management | 1 | 2019 | 248 | 0.040 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2017 | 151 | 0.030 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2022 | 767 | 0.030 |
Why?
|
| Recombinant Fusion Proteins | 1 | 2017 | 376 | 0.030 |
Why?
|
| Pilot Projects | 1 | 2020 | 1342 | 0.030 |
Why?
|
| Proportional Hazards Models | 1 | 2017 | 792 | 0.030 |
Why?
|
| Conversion to Open Surgery | 1 | 2015 | 6 | 0.030 |
Why?
|
| Contraindications | 1 | 2015 | 52 | 0.030 |
Why?
|
| Immunoglobulin G | 1 | 2017 | 481 | 0.030 |
Why?
|
| Antibodies, Monoclonal | 1 | 2017 | 511 | 0.030 |
Why?
|
| Emergency Service, Hospital | 1 | 2020 | 711 | 0.030 |
Why?
|
| Registries | 1 | 2017 | 733 | 0.030 |
Why?
|
| Hospital Mortality | 1 | 2015 | 384 | 0.030 |
Why?
|
| Cystectomy | 1 | 2012 | 13 | 0.030 |
Why?
|
| Urination | 1 | 2012 | 19 | 0.030 |
Why?
|
| Patient Readmission | 1 | 2015 | 267 | 0.030 |
Why?
|
| Headache | 1 | 2012 | 68 | 0.030 |
Why?
|
| Infant | 1 | 2018 | 2891 | 0.020 |
Why?
|
| Length of Stay | 1 | 2015 | 780 | 0.020 |
Why?
|